MEP16808A - Substituted benzimidazole compounds and their use for the treatment of cancer - Google Patents

Substituted benzimidazole compounds and their use for the treatment of cancer

Info

Publication number
MEP16808A
MEP16808A MEP-168/08A MEP16808A MEP16808A ME P16808 A MEP16808 A ME P16808A ME P16808 A MEP16808 A ME P16808A ME P16808 A MEP16808 A ME P16808A
Authority
ME
Montenegro
Prior art keywords
cancer
treatment
benzimidazole compounds
substituted benzimidazole
compounds
Prior art date
Application number
MEP-168/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Francois Clerc
Francois Hamy
Isabelle Depaty
Angouillant-Boniface
Stephanie Deprets
Manfred Carrez
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP16808A publication Critical patent/MEP16808A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30Nitrogen atoms not forming part of a nitro radical
    • C07D235/32Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MEP-168/08A 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer MEP16808A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01402460A EP1298125A1 (fr) 2001-09-26 2001-09-26 Benzimidazoles substitués et leur usage comme traitement du cancer
YUP-214/04A RS50896B (sr) 2001-09-26 2002-09-26 Supstituisana jedinjenja benzimidazola i njihova primena u lečenju raka
PCT/EP2002/011353 WO2003028721A2 (fr) 2001-09-26 2002-09-26 Composes de benzimidazole substitue et utilisation de ceux-ci pour le traitement du cancer

Publications (1)

Publication Number Publication Date
MEP16808A true MEP16808A (en) 2010-06-10

Family

ID=8182891

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-168/08A MEP16808A (en) 2001-09-26 2002-09-26 Substituted benzimidazole compounds and their use for the treatment of cancer

Country Status (35)

Country Link
US (1) US7041668B2 (fr)
EP (2) EP1298125A1 (fr)
JP (1) JP4510450B2 (fr)
KR (1) KR100891439B1 (fr)
CN (1) CN100346786C (fr)
AR (1) AR037096A1 (fr)
AT (1) ATE386517T1 (fr)
AU (1) AU2002337151B2 (fr)
BR (1) BR0212856A (fr)
CA (1) CA2461622C (fr)
CO (1) CO5570675A2 (fr)
CY (1) CY1107953T1 (fr)
DE (1) DE60225159T2 (fr)
DK (1) DK1432417T3 (fr)
EA (1) EA006802B1 (fr)
ES (1) ES2301682T3 (fr)
GT (1) GT200200190A (fr)
HK (1) HK1068551A1 (fr)
HR (1) HRPK20040293B3 (fr)
HU (1) HUP0401756A3 (fr)
IL (1) IL161059A0 (fr)
ME (1) MEP16808A (fr)
MX (1) MXPA04002042A (fr)
MY (1) MY135339A (fr)
NO (1) NO327008B1 (fr)
NZ (1) NZ531246A (fr)
PA (1) PA8555501A1 (fr)
PE (1) PE20030427A1 (fr)
PL (1) PL369527A1 (fr)
PT (1) PT1432417E (fr)
RS (1) RS50896B (fr)
SI (1) SI1432417T1 (fr)
UY (1) UY27452A1 (fr)
WO (1) WO2003028721A2 (fr)
ZA (1) ZA200401887B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011250847B2 (en) * 2003-06-23 2013-06-20 Bhi Limited Partnership Methods and compositions for treating amyloid-related diseases
US20070010573A1 (en) 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US20070208166A1 (en) * 2003-10-24 2007-09-06 Exelixis, Inc. Tao Kinase Modulators And Method Of Use
DE102004010207A1 (de) 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
FR2868421B1 (fr) * 2004-04-01 2008-08-01 Aventis Pharma Sa Nouveaux benzothiazoles et leur utilisation comme medicaments
EP1598348A1 (fr) 2004-05-18 2005-11-23 Aventis Pharma Deutschland GmbH Dérivés de pyridazinone comme inhibiteurs de CDK2
CA2900876A1 (fr) 2004-12-22 2006-08-17 Bhi Limited Partnership Methodes et compositions de traitement de maladies liees a l'amyloide
CN101300251B (zh) * 2005-09-06 2011-08-03 史密丝克莱恩比彻姆公司 作为plk抑制剂的苯并咪唑噻吩化合物
FR2891273B1 (fr) * 2005-09-27 2007-11-23 Aventis Pharma Sa NOUVEAUX DERIVES BENZIMIDAZOLES ET BENZOTHIAZOLES, LEUR PREPARATION ET LEUR UTILISATION PHARMACEUTIQUE NOTAMMENT COMME INHIBITEURS DE CMet
KR101443573B1 (ko) 2006-10-12 2014-11-03 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
PA8792501A1 (es) 2007-08-09 2009-04-23 Sanofi Aventis Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol,su procedimiento de preparación,su aplicación como medicamentos,composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
KR20160039312A (ko) * 2007-10-12 2016-04-08 애브비 바하마스 리미티드 2-((r)-2-메틸피롤리딘-2-일)-1h-벤즈이미다졸-4-카복스아미드 결정형 1
FR2922550B1 (fr) 2007-10-19 2009-11-27 Sanofi Aventis Nouveaux derives de 6-aryl/heteroalkyloxy benzothiazole et benzimidazole, application comme medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de cmet
FR2941949B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-cycloalkyl ou 6-nh-cycloalkyl- triazolopyridazine-sulfanyl)benzothiazoles et benzimidazoles preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941950B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-o-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941951B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-nh-substitue-triazolopyridazine-sulfanyl) benzothiazoles et benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
FR2941952B1 (fr) 2009-02-06 2011-04-01 Sanofi Aventis Derives de 6-(6-substitue-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles et 5-fluoro-benzimidazoles : preparation, application comme medicaments et utilisation comme inhibiteurs de met.
WO2011091152A1 (fr) * 2010-01-22 2011-07-28 Pablo Gastaminza Inhibiteurs d'infection par le virus de l'hépatite c
WO2017035340A1 (fr) 2015-08-25 2017-03-02 Alnylam Pharmaceuticals, Inc. Procédés et compositions pour le traitement d'un trouble associé à un gène de proprotéine convertase subtilisine kexine (pcsk9)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2441201C2 (de) * 1974-08-28 1986-08-07 Hoechst Ag, 6230 Frankfurt Anthelminthisch wirksame 2-Carbalkoxyamino-5(6)-phenyl-sulfonyloxy-benzimidazole und Verfahren zu ihrer Herstellung
DE2541752A1 (de) * 1975-09-19 1977-03-24 Hoechst Ag Anthelminthisch wirksame 2-carbalkoxyamino-5(6)-phenyl-sulfonyloxy- benzimidazole und verfahren zu ihrer herstellung
DE3247615A1 (de) * 1982-12-23 1984-07-05 Hoechst Ag, 6230 Frankfurt Substituierte phenylsulfonyloxybenzimidazolcarbaminate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB9900752D0 (en) * 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
US6693125B2 (en) * 2001-01-24 2004-02-17 Combinatorx Incorporated Combinations of drugs (e.g., a benzimidazole and pentamidine) for the treatment of neoplastic disorders

Also Published As

Publication number Publication date
CA2461622A1 (fr) 2003-04-10
KR100891439B1 (ko) 2009-04-03
MY135339A (en) 2008-03-31
SI1432417T1 (sl) 2008-08-31
JP2005504112A (ja) 2005-02-10
CY1107953T1 (el) 2013-09-04
WO2003028721A3 (fr) 2003-12-11
HRP20040293A2 (en) 2005-06-30
NZ531246A (en) 2006-06-30
NO20041214L (no) 2004-06-24
PA8555501A1 (es) 2003-06-30
PT1432417E (pt) 2008-05-23
US7041668B2 (en) 2006-05-09
NO327008B1 (no) 2009-04-06
EP1432417A2 (fr) 2004-06-30
GT200200190A (es) 2003-11-11
JP4510450B2 (ja) 2010-07-21
AR037096A1 (es) 2004-10-20
CN100346786C (zh) 2007-11-07
KR20040048904A (ko) 2004-06-10
BR0212856A (pt) 2004-09-14
CA2461622C (fr) 2008-12-02
ATE386517T1 (de) 2008-03-15
US20050014811A1 (en) 2005-01-20
DE60225159D1 (de) 2008-04-03
RS50896B (sr) 2010-08-31
DE60225159T2 (de) 2009-02-19
HUP0401756A2 (hu) 2005-01-28
HK1068551A1 (en) 2005-04-29
CN1558761A (zh) 2004-12-29
EA006802B1 (ru) 2006-04-28
YU21404A (sh) 2006-08-17
PL369527A1 (en) 2005-05-02
ZA200401887B (en) 2005-05-31
EA200400475A1 (ru) 2004-08-26
HRPK20040293B3 (en) 2007-06-30
HUP0401756A3 (en) 2005-06-28
AU2002337151B2 (en) 2007-04-26
EP1298125A1 (fr) 2003-04-02
MXPA04002042A (es) 2004-06-07
ES2301682T3 (es) 2008-07-01
EP1432417B1 (fr) 2008-02-20
IL161059A0 (en) 2004-08-31
UY27452A1 (es) 2003-02-28
CO5570675A2 (es) 2005-10-31
DK1432417T3 (da) 2008-06-16
PE20030427A1 (es) 2003-06-20
WO2003028721A2 (fr) 2003-04-10

Similar Documents

Publication Publication Date Title
MEP16808A (en) Substituted benzimidazole compounds and their use for the treatment of cancer
DE60112312D1 (de) Imidazolderivate als raf-kinase-inhibitoren
CY1105477T1 (el) Αναστολεις τρανσφepασης φαρνεσυλ πρωτεϊνης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
SE0101387D0 (sv) Novel compounds
ME00142B (me) Derivati pirazolo-hinazolina, postupci za njihovo dobijanje i njihova upotreba kao inhibitora kinaze
BRPI0415525A (pt) derivados de imidazola e seu uso como agentes farmacêuticos
NO20071875L (no) Bicykliske amider som kinaseinhibitorer
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
EE200300475A (et) Türosiini kinaasi inhibiitorid, neid sisaldavad ravimkoostised ja nimetatud ühendid kasutamiseks haiguste ravis
DE60206911D1 (de) Imidazol-2-carbonsäureamid derivate als raf-kinase-inhibitoren
SE0301700D0 (sv) Novel compounds
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
MX2007002269A (es) Uso novedoso de compuestos peptidos para tratar dolor por c??ncer de huesos, dolor inducido por quimioterapia y nucleosidos.
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
DE602004020070D1 (de) Thienopyrimidin-derivate als kaliumkanal-inhibitoren
SE0302546D0 (sv) New compounds
SE0300098D0 (sv) Use of cyclin D1 inhibitors
TR200101693T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
GB0121494D0 (en) Compounds
DE60213798D1 (de) Carbolinderivate als pdev inhibitoren
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
ATE431348T1 (de) Thiaepothilone zur behandlung von krebserkrankungen
ECSP034516A (es) Compuestos de pirazol utiles como inhibidores de protein quinasa